Chemicals & Small Molecules

Necitumumab (IMC-11F8) is a human monoclonal antibody directed against the epidermal growth factor (EGF) receptor, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer, and may be used in cancer research.

PF-03732010 is a CHO-expressed humanized antibody targeting P-calmodulin with anti-tumor and anti-metastatic activity, inhibiting primary tumor growth and metastatic progression.

Ocrelizumab (IDC-2403) is a humanized monoclonal antibody directed against CD20 for the treatment of multiple sclerosis.

Icatolimab (JS-004) is a humanized antibody targeting BTLA/CD272 for the study of lymphomas and solid tumors.

LCKLSL hydrochloride is a hexapeptide compound and competitive inhibitor of membrane-bound protein A2 (AnxA2) with potential anti-angiogenic activity that inhibits the development of autoimmune encephalomyelitis (EAE) in mice.

MOG peptide (35-55) amide, a myelin oligodendrocyte glycoprotein (MOG) fragment spanning amino acids 35 to 55, selectively stimulates CD4+ T cell expansion and induces experimental autoimmune encephalomyelitis (EAE) in animal models [1] [2] [3].

ELOVL6-IN-1 is a potent, selective, and orally active inhibitor of ELOVL6, exhibiting dose-dependent inhibition of mouse ELOVL6 with an IC50 of 0.350 μM and acting as a noncompetitive inhibitor with respect to malonyl-CoA (Ki=994 nM) and palmitoyl-CoA [1].

Bleximenib oxalate (Menin-MLL inhibitor 24 oxalate) is a selective and highly efficient menin-MLL inhibitor. It shows antiproliferative activity in acute lymphoblastic leukemia (ALL) cell lines and inhibits the binding of the menin-KMT2A complex to chromatin at the target gene promoter.

NH2-UAMC1110 TFA is a derivative of UAMC1110 bearing an aminobutoxy group for the synthesis of FAPI-QS. UAMC1110 is a novel selective fibroblast-activated protein (fap) inhibitor exhibiting low nanomolar inhibition of the related dipeptidyl peptidases (dpps), dppiv, dpp9, dppii, and (prep). dppiv, dpp9, dppii, and (prep).